BR112023006761A2 - Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos - Google Patents
Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmosInfo
- Publication number
- BR112023006761A2 BR112023006761A2 BR112023006761A BR112023006761A BR112023006761A2 BR 112023006761 A2 BR112023006761 A2 BR 112023006761A2 BR 112023006761 A BR112023006761 A BR 112023006761A BR 112023006761 A BR112023006761 A BR 112023006761A BR 112023006761 A2 BR112023006761 A2 BR 112023006761A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- peptide compounds
- short ring
- ring modified
- modified proline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003147 proline derivatives Chemical class 0.000 title abstract 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos. a invenção refere-se a um composto de peptídeo curto de prolina modificado no anel e ao uso do mesmo, e especificamente a invenção se refere a um composto representado pela fórmula (x) ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110413867 | 2021-04-16 | ||
CN202110517743 | 2021-05-12 | ||
CN202110637580 | 2021-06-08 | ||
CN202110659242 | 2021-06-11 | ||
CN202110879570 | 2021-07-30 | ||
CN202111040878 | 2021-09-06 | ||
CN202111088812 | 2021-09-16 | ||
CN202111307043 | 2021-11-05 | ||
CN202111343012 | 2021-11-12 | ||
CN202111433962 | 2021-11-29 | ||
CN202111567163 | 2021-12-20 | ||
CN202210029887 | 2022-01-12 | ||
CN202210170046 | 2022-02-23 | ||
PCT/CN2022/087511 WO2022218442A1 (zh) | 2021-04-16 | 2022-04-18 | 环修饰的脯氨酸短肽化合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023006761A2 true BR112023006761A2 (pt) | 2024-02-06 |
Family
ID=83640162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023006761A BR112023006761A2 (pt) | 2021-04-16 | 2022-04-18 | Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230312571A1 (pt) |
EP (1) | EP4209494A4 (pt) |
JP (1) | JP7469562B2 (pt) |
KR (1) | KR20230107825A (pt) |
CN (2) | CN115698012B (pt) |
AU (1) | AU2022258377B2 (pt) |
BR (1) | BR112023006761A2 (pt) |
CA (1) | CA3201360A1 (pt) |
CO (1) | CO2023015419A2 (pt) |
IL (1) | IL307443A (pt) |
WO (1) | WO2022218442A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2922973T1 (es) * | 2020-07-20 | 2022-09-22 | Enanta Pharm Inc | Peptidos funcionalizados como agentes antivirales |
IL302990A (en) | 2020-11-23 | 2023-07-01 | Enanta Pharm Inc | Antivirals that are derivatives of the novel spiropyrrolidine |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
WO2023088418A1 (en) * | 2021-11-20 | 2023-05-25 | Fochon Biosciences, Ltd. | Compounds as sars-cov-2 inhibitors |
CN118176202A (zh) * | 2022-10-14 | 2024-06-11 | 福建广生中霖生物科技有限公司 | 一种含氰基取代的多肽类化合物的晶型及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100939155B1 (ko) * | 2000-07-21 | 2010-01-28 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3-세린 프로테아제 억제제로서의신규한 펩티드 |
WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
WO2011094426A1 (en) * | 2010-01-29 | 2011-08-04 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Caspase inhibitors |
WO2013111158A2 (en) * | 2012-01-03 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of dpp-iv inhibitor |
PL227285B1 (pl) * | 2014-10-02 | 2017-11-30 | Politechnika Wroclawska | Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia watroby typu C (HCV) |
TW201817714A (zh) * | 2016-08-30 | 2018-05-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抑制3c及3cl蛋白酶之化合物及其使用方法 |
CN116236580B (zh) * | 2020-02-21 | 2024-05-24 | 中国科学院上海药物研究所 | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 |
WO2021207409A2 (en) * | 2020-04-08 | 2021-10-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof |
US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
TW202216663A (zh) * | 2020-06-09 | 2022-05-01 | 美商帕迪斯生物科學公司 | 半胱胺酸蛋白酶抑制劑及其使用方法 |
BR112022025037A2 (pt) * | 2020-06-10 | 2023-02-14 | Aligos Therapeutics Inc | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus |
ES2922973T1 (es) * | 2020-07-20 | 2022-09-22 | Enanta Pharm Inc | Peptidos funcionalizados como agentes antivirales |
WO2022020711A1 (en) * | 2020-07-24 | 2022-01-27 | The Texas A&M University System | Sars-cov-2 main protease inhibitors |
CN115960088A (zh) * | 2020-07-31 | 2023-04-14 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN114426568B (zh) * | 2022-01-11 | 2023-04-25 | 嘉兴安谛康生物科技有限公司 | 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途 |
-
2022
- 2022-04-18 BR BR112023006761A patent/BR112023006761A2/pt unknown
- 2022-04-18 AU AU2022258377A patent/AU2022258377B2/en active Active
- 2022-04-18 WO PCT/CN2022/087511 patent/WO2022218442A1/zh active Application Filing
- 2022-04-18 CN CN202280005041.2A patent/CN115698012B/zh active Active
- 2022-04-18 JP JP2023518312A patent/JP7469562B2/ja active Active
- 2022-04-18 KR KR1020237018146A patent/KR20230107825A/ko active IP Right Grant
- 2022-04-18 CA CA3201360A patent/CA3201360A1/en active Pending
- 2022-04-18 EP EP22787664.6A patent/EP4209494A4/en active Pending
- 2022-04-18 CN CN202310972706.3A patent/CN117003813B/zh active Active
- 2022-04-18 IL IL307443A patent/IL307443A/en unknown
-
2023
- 2023-04-25 US US18/306,236 patent/US20230312571A1/en active Pending
- 2023-11-15 CO CONC2023/0015419A patent/CO2023015419A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022258377A1 (en) | 2023-05-04 |
JP7469562B2 (ja) | 2024-04-16 |
CO2023015419A2 (es) | 2023-11-20 |
IL307443A (en) | 2023-12-01 |
WO2022218442A1 (zh) | 2022-10-20 |
CA3201360A1 (en) | 2022-10-20 |
CN115698012B (zh) | 2023-06-16 |
AU2022258377A9 (en) | 2024-04-18 |
JP2023543729A (ja) | 2023-10-18 |
EP4209494A1 (en) | 2023-07-12 |
CN117003813B (zh) | 2024-03-08 |
US20230312571A1 (en) | 2023-10-05 |
CN115698012A (zh) | 2023-02-03 |
EP4209494A4 (en) | 2023-10-04 |
KR20230107825A (ko) | 2023-07-18 |
CN117003813A (zh) | 2023-11-07 |
AU2022258377B2 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023006761A2 (pt) | Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos | |
MX2022015207A (es) | Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus. | |
MX2022014458A (es) | Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo. | |
CY1119261T1 (el) | Παραγωγα θειαζολιου | |
MX2022005839A (es) | Compuestos utiles como inhibidores de la proteina helios. | |
EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
AP2003002915A0 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. | |
CY1114892T1 (el) | Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
BRPI0809977A8 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
NO20006282D0 (no) | Nye cyklosporiner | |
NO20034660L (no) | Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
SE0302192D0 (sv) | Novel compounds | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
EA200400086A1 (ru) | Новые производные оксазолидинонов в качестве антибактериальных агентов | |
AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
BR0214842A (pt) | Inibidores de integrase hiv | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |